Dr. Walter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1100 Fairview Ave N, D1-100
Seattle, WA 98109- Is this information wrong?
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
- University of Zurich Faculty of MedicineClass of 1996
Certifications & Licensure
- WA State Medical License 2006 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2008 Mar 01
- Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2008 Dec 01
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Start of enrollment: 2009 May 01
- Join now to see all
Publications & Presentations
PubMed
- CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.Scott R Solomon, Bayard L Powell, Jamie Koprivnikar, Catherine Lai, Heather Male, Laura C Michaelis, Laura F Newell, David Sanford, Jack Jenkins, Amy Zelaya, Sheryl Co...> ;Cancers. 2024 Feb 24
- Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Daniel J Olivieri, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M Sandmaier, Irum Khan, Chris Davis, Ryan S Basom, Frederick R Appelb...> ;Leukemia. 2024 Apr 1
- Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKETCC-96191.Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, Mark T Orr, Heidi K Jessup, Heather J Thomas, Henry Chan, Mahan A Jahromi, Jonathan Lloyd, Ann F Cheung, Grego...> ;Cancers. 2024 Feb 22
- Join now to see all
Journal Articles
- Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
- Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG TrialsBrent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature
- Relationship Between CD33 Expression, Splicing Polymorphism, and in Vitro Cytotoxicity of Gemtuzumab Ozogamicin and the CD33/CD3 BiTErAMG 330Colin D Godwin, Roland B Walter, Haematologica
- Join now to see all
Abstracts/Posters
- Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone MarrowRoland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable RemissionsRoland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRoland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- MRD and Relapse in Patients with AMLAugust 17th, 2022
- NCI Partners with Cancer Research UK, JADPRO Appoints Beth Faiman as Editor-in-Chief, and MoreOctober 1st, 2020
- Shop TalkSeptember 5th, 2020
- Join now to see all
Grant Support
- Prognostic And Functional Significance Of Adhesion Molecules In Pediatric AMLNational Cancer Institute2012
- Impact Of Genetic Variation On Response To GO Therapy In Cog-Aml Clinical TrialsNational Cancer Institute2012
- AML Stem Cell Heterogeneity: Implications For Gemtuzumab Ozogomicin-Based TherapyNational Cancer Institute2009
Hospital Affiliations
- UW Medicine/University of Washington Medical CenterSeattle, Washington
- Fred Hutchinson Cancer CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: